---
document_datetime: 2026-01-16 15:50:08
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aripiprazole-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: aripiprazole-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.4102675
conversion_datetime: 2026-01-17 13:26:28.933854
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Aripiprazole Zentiva

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 16/01/2026                          |                                             | PL                               |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000321433                      | Update of the package leaflet with revised contact details of local representative.                                                                                                                                                                                                                          |            |                        |                  |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|------------------|
| Article 61(3) /                       | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representatives. Furthermore, the PI has been brought in line with the latest QRD template (version 10.4).                                                                                  | 15/07/2025 | PL                     | EMA/N/0000284695 |
| Variation type IB / EMA/VR/0000256773 | C.I.7 Deletion of: - C.I.7.a a pharmaceutical form - Accepted C.I.7.a (Type IB) Deletion of the presentations related to the orodispersible tablets pharmaceutical form. The following presentations will be deleted: 10 mg (EU/1/15/1009/021-23), 15 mg (EU/1/15/1009/024-26), 30 mg (EU/1/15/1009/027-29). | 17/06/2025 | SmPC, Labelling and PL |                  |